Breastcancer.org Joins My Breast Cancer Coach to Provide Newly Diagnosed Patients With Online Personalized Treatment Information

The new Coach launches today with updated information and new
features, and is available from the homepages of Breastcancer.org and
Breast Cancer Network of Strength, and online at
www.MyTreatmentDecision.com. Coach walks patients through a simple
questionnaire narrated by breast cancer survivor Lillie Shockney, RN,
Administrative Director of the Johns Hopkins Avon Foundation Breast
Center, who gives audio advice to help patients better understand
their individual breast cancer diagnosis. Based on the information
provided by the patient, Coach yields a customized report for
patients to share with their doctor as they discuss treatment
options. Since it first launched in spring 2008, more than 24,000
patients have visited My Breast Cancer Coach.

"Those first few weeks following a breast cancer diagnosis can be
particularly confusing for a patient, when emotions are raw and there
is so much information to sift through," said Hope Wohl, CEO of
Breastcancer.org. "Our organization saw My Breast Cancer Coach as a
unique guide for patients at this critical juncture. Collaborating
with Genomic Health and Breast Cancer Network of Strength on this
important project helps us further fulfill our mission."

The updated My Breast Cancer Coach now includes a host of important
new resources, including information for Stage 0 breast cancer
patients, a podcast series, and an expert Q&A, all designed to
address the questions and concerns of newly diagnosed patients.

Breast Cancer Network of Strength is a founding partner of Coach, and
was joined this year by Breastcancer.org. "We are proud to be a part
of the new My Breast Cancer Coach, which is more interactive and
dynamic than ever," said Margaret C. Kirk, President and CEO of
Breast Cancer Network of Strength. "The breast cancer community
embraced this tool when it was first available, and we helped to make
it even better."

"Every patient's breast cancer diagnosis is different, and calls for
a unique treatment approach," said Kim Popovits, President and CEO of
Genomic Health. "Genomic Health is committed to helping physicians
and patients improve treatment decisions through genomic analysis.
My Breast Cancer Coach teaches patients that breast cancer is not a
one-size-fits-all disease and that they should work with their doctor
to tailor a treatment course that's right for them."

About Genomic Health, Inc.

Genomic Health, Inc. (NASDAQ: GHDX | Quote | Chart | News | PowerRating) is a life science company focused
on the development and commercialization of genomic-based clinical
laboratory services for cancer that allow physicians and patients to
make individualized treatment decisions. In 2004, Genomic Health
launched the Oncotype DX(R) breast cancer test, which has been shown
to predict the likelihood of chemotherapy benefit as well as
recurrence in early-stage breast cancer. In addition to the widely
adopted Oncotype DX breast cancer test, Genomic Health is preparing
to launch its Oncotype DX colon cancer test in early 2010. The
company was founded in 2000 and is located in Redwood City,
California. For more information, please visit www.genomichealth.com.

About Breastcancer.org and Breast Cancer Network of Strength

Breastcancer.org (http://www.breastcancer.org/) offers comprehensive,
easy to understand information about breast cancer, as well as online
discussion boards and chat rooms in the "Community Knowledge" section
of its Web site. Breast Cancer Network of Strength
(www.networkofstrength.org) has online message boards and
YourShoes(TM), a free, 24-hour breast cancer support line staffed by
trained peer counselors who are also breast cancer survivors. Call
Your Shoes at 1-800-221-2141 any time for immediate emotional
support.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to Genomic Health's plans to
commercialize a test for colon cancer and the proposed timing of such
commercialization. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: the risks and potential delays associated with
commercialization of a new test; the risks and uncertainties
associated with the regulation of the company's tests; the
applicability of clinical study results to actual outcomes; and the
other risks set forth in Genomic Health's filings with the Securities
and Exchange Commission, including the risks set forth in Genomic
Health's Quarterly Report on Form 10-Q for the quarter ended June 30,
2009. These forward-looking statements speak only as of the date
hereof. Genomic Health disclaims any obligation to update these
forward-looking statements.

Links to third-party websites or pages are provided for convenience
only. Each website is subject to its own terms of use, and we
encourage you to consult these policy statements. Genomic Health has
no control over third party sites and does not endorse or recommend
these sites, and expressly disclaims any responsibility for the
accuracy of content or opinions set forth in any third party website
or your use of that information. In addition, Genomic Health
disclaims all liability arising out of allegations that third party
content infringes the intellectual property rights of any person.
Information in this release should not be considered medical advice.
Patients should consult their doctor to determine the appropriate
treatment decision for their individual disease.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence
Score are trademarks or registered trademarks of Genomic Health, Inc.
All other trademarks and service marks are the property of their
respective owners.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1083121

Contact:
Shannon Richardson
Spectrum Science
srichardson@spectrumscience.com
(202) 955-6222

SOURCE: Breastcancer.org; Breast Cancer Network of Strength; Genomic Health

mailto:srichardson@spectrumscience.com

For full details on Genomic Health Inc (GHDX) GHDX. Genomic Health Inc (GHDX) has Short Term PowerRatings at TradingMarkets. Details on Genomic Health Inc (GHDX) Short Term PowerRatings is available at This Link.